- Business Wire•6 days agoAntibe Therapeutics Confirms Non-Addictive Properties for Its Second Pipeline Drug, ATB-352, a Potent, Non-Addictive Pain-Killer
Antibe Therapeutics Inc. is pleased to provide an update on it second pipeline drug, ATB-352, a potent pain-killer intended for the relief of acute, severe pain.
- Business Wire•8 days ago
Antibe Therapeutics Inc. announces it has elected to pay in kind all interest due October 15, 2016 under the Company’s 10% senior secured convertible debentures due October 15, 2018 .
- Business Wire•12 days agoAntibe Therapeutics Announces Launch of Strategic Growth Initiative in the U.S. Market for Dental Biologics
Antibe Therapeutics Inc. , a commercial-stage pharmaceutical growth company, today announces that its subsidiary Citagenix Inc. is launching a strategic initiative to drive growth of product sales in the U.S.
Antibe Therapeutics Inc. (ATE.V)
TSXV - TSXV Delayed Price. Currency in CAD
|Day's Range||0.17 - 0.18|
|52wk Range||0.10 - 0.27|
|1y Target Est||N/A|
|P/E Ratio (ttm)||-3.83|
|Avg Vol (3m)||117,200|
|Dividend & Yield||N/A (N/A)|